GlassScriptPhysician profile
Lawrence T Sinatra
NPI 1942200209
$1,407.18
in general payments reported to CMS, 2019-2025
24 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $207 · 2021: $341 · 2022: $144 · 2023: $232 · 2024: $140 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $197.34 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.46 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $126.70 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $108.93 | 2019-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $108.32 | 2019-2021 | |
| Novo Nordisk INC | $104.13 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $103.42 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Lilly USA, LLC | $85.08 | 2021-2023 | Emgality, Jardiance |
| Exact Sciences Corporation | $53.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $53.36 | 2019-2020 | |
| Pfizer INC. | $49.44 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $37.49 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $37.42 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $32.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $31.38 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $21.53 | 2023 | Sapien 3 Ultra Resilia |
| Upsher-Smith Laboratories LLC | $16.92 | 2021 | |
| Insulet Corporation | $16.15 | 2025 | Omnipod |
| Dexcom, INC. | $15.84 | 2024 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $15.67 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.20 | 2023 | |
| Amgen INC. | $13.48 | 2025 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $12.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Sinatra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.